2023年5月12日 · 低分子肝素：依诺肝素是目前国内外指南唯一推荐的用于 acs 患者 pci 围术期的 lmwh，广泛适用于 stemi 和 nste-acs 患者。 鉴于其他 LMWH 在 PCI 围术期疗效和安全性的证据不足，不能替代依诺肝素。

2023年4月3日 · UFH vs. LMWH. LMWH is generally preferable for the following reasons: LMWH is easier to give logistically (doesn't require IV infusion or monitoring). LMWH has a decreased risk of heparin induced thrombocytopenia with thrombosis (HIT). Studies comparing UFH and LMWH generally show that LMWH is more effective and causes less bleeding.

2024年6月6日 · One of the main differences between the two types of heparins is how you get them. You get UFH through an IV, usually at a hospital, but you can inject yourself with LMWH at home. UFH works...

Mismetti et al 9 showed that in general surgery, the efficacy and safety of low-molecular-weight heparin (LMWH) relative to unfractionated heparin (UFH) were similar in patients with vs those without cancer. However, estimates of the relative effects of the 2 medications in patients with cancer were not provided.

Both unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) have established roles in preventing and treating venous thromboembolism (VTE) and as adjuvant therapies for atherothrombotic syndromes. 1,2 Numerous studies have compared the efficacy and safety of …

Heparin is a natural agent used to prevent clot formation in the vessels. Two types of heparins are widely used, unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin‐induced thrombocytopenia (HIT) is an adverse reaction that …

2001年7月1日 · Reduced binding to plasma proteins and cells is responsible for the more predictable dose-response relationship of LMWH, longer plasma half-life (compared with UFH), and lower risk of heparin-induced thrombocytopenia and osteopenia.

1998年10月13日 · LMWHs are derived from UFH by chemical or enzymatic depolymerization to yield fragments that are approximately one third the size of heparin. Like UFH, they are heterogeneous with respect to molecular size and anticoagulant activity. LMWHs have a mean molecular weight of 4000 to 5000, with a molecular weight distribution of 1000 to 10 000.

All studies involved adjustment of treatment with UFH to a specified target-activated partial thromboplastin time range, and all patients received either LMWH or UFH for at least 5 days. The maximum duration of injectable anticoagulant administration was 10 days.

ufh和lmwh不同，磺达肝癸钠预期不与血小板因子 iv结合，也不与来自肝素诱导血小板减少症患者的血 浆发生交叉反应。与lmwh相比，磺达肝癸钠具有独 特的抗凝活性和更长的半衰期（10~15h)。磺达肝癸 钠于2009年在我国获批上市，该药在中国、欧洲、美国